Published in Health and Medicine Week, June 22nd, 2006
ISA247 is a calcineurin inhibitor currently being investigated in a phase III trial for the treatment of moderate-to-severe psoriasis and a phase IIb trial for the prevention of organ rejection following transplantation.
Under the terms of the agreement:
1) Lux Biosciences, Inc., will make upfront and milestone payments to Isotechnika. Assuming...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.